paclitaxel has been researched along with Brain Ischemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Copur, MS; DeSpiegelaere, H; Ganti, AK; Huerter, MM; Kessinger, A; Ketcham, M; Kos, ME; Kruse, S; Marr, AS; Meza, JL; Radniecki, SE; Swenson, K; Tolentino, A | 1 |
Gong, JJ; Guan, QH; Qi, SH; Sun, FM; Wang, M; Yue, J; Zhao, H | 1 |
1 trial(s) available for paclitaxel and Brain Ischemia
Article | Year |
---|---|
Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Early Termination of Clinical Trials; Female; Heart Arrest; Humans; Hypoxia; Lung Neoplasms; Lymphopenia; Male; Neutropenia; Paclitaxel; Pneumonia; Quality of Life; Respiratory Insufficiency; Survival Rate; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2017 |
1 other study(ies) available for paclitaxel and Brain Ischemia
Article | Year |
---|---|
Neuroprotection of paclitaxel against cerebral ischemia/reperfusion-induced brain injury through JNK3 signaling pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Ischemia; Caspase 3; Cell Death; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 10; Mitogen-Activated Protein Kinase Kinase Kinase 11; Neurons; Neuroprotective Agents; Paclitaxel; Phosphorylation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Tubulin Modulators | 2011 |